Abstract
Esophageal cancer is a highly aggressive tumor often associated with poor prognosis. Globally the incidence and prevalence rates of esophageal cancer vary a lot. Genetic and phenotypic variations in different populations have variable survival outcomes. Concurrent chemoradiation as per Cross Trial is standard of care and now being widely used in Pakistan, however there is scarcity of data in our population. This study aims at identifying the disease-free survival of patients treated with Cross trial in our tertiary care institute.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
